CERE INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Cerevel Therapeutics Holdings, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jun 02 2025
0mins
Source: Globenewswire
Class Action Lawsuit Filed: A class action lawsuit has been initiated against Cerevel Therapeutics, Bain Capital, and Pfizer for alleged violations of federal securities laws, impacting investors who sold or held shares during specific periods related to a merger with AbbVie.
Allegations of Misleading Information: The complaint claims that Cerevel's offering documents omitted crucial information about AbbVie's acquisition interest, leading to an artificially low stock price before the merger announcement, which benefitted Bain significantly.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
